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Abstract. Blood‑derived microRNAs (miRNAs/miRs) are 
ideal clinical biomarkers, as they can be relatively non‑inva‑
sively extracted and are stable across a range of storage 
conditions. However, the concentration and profile of miRNAs 
differ between specific patient groups and starting media, 
which must be a key consideration before embarking upon uses 
for clinical applications. The optimum blood‑derived starting 
media for biomarker discovery involving pregnant women 
with an uncomplicated pregnancy has not been determined. 
Paired serum and plasma samples were collected from 10 
pregnant women with uncomplicated low‑risk pregnancies at 
three time points: i) During the second trimester of pregnancy; 
ii) during the third trimester; and iii) 6 weeks post‑partum. 
Sample miRNA content was assessed using an Agilent 
Bioanalyzer Small RNA chip and reverse transcription‑quan‑
titative (RT‑q)PCR using four constitutively expressed 
miRNAs: hsa‑miR‑222‑3p, hsa‑miR‑23a, hsa‑miR‑30e‑5p 
and hsa‑miR‑451a. Quality control spike‑ins measured RNA 
extraction (UniSp2) and cDNA extraction (cel‑miR‑39‑3p) 
efficiency. MiRNA concentration and percentage were signifi‑
cantly higher in the serum vs. plasma samples based on data 
obtained from the Bioanalyzer; however, RT‑qPCR failed to 
replicate these differences in the majority of comparisons 
using the ΔCq values of the four constitutively expressed 
miRNAs. Using the standard deviations of the ΔCq values, the 
consistency of serum and plasma in terms of miRNA expres‑
sion levels were equivalent. Thus, clinicians and researchers 
should take into consideration that different miRNA quantifi‑
cation methods can yield contrasting results with regards to the 
starting media utilized. Based on the equivalent performance 
of serum and plasma assessed using RT‑qPCR, which is less 
likely to be influenced by the coagulation process or degraded 
long RNAs, both starting media assessed in the present study 
are equally suitable for ongoing biomarker discovery studies 
involving healthy pregnant women at any gestational time 
point or immediately postpartum.
Introduction
Over the past 10‑15 years, scientific interest in microRNAs 
(miRNA/miRs) and their roles as modern, discriminatory 
biomarkers has grown exponentially (1‑3). Now, this small 
(18‑24 nucleotide) non‑coding molecule encapsulates one of 
the most thriving, sought after areas of research. MiRNAs 
have been implicated in several disease processes, particu‑
larly in oncology, with the potential to facilitate diagnosis 
and predict disease development earlier than is currently 
possible (4‑7). Furthermore, miRNAs have been suggested 
to confer overall prognosis, survival, drug sensitivity, treat‑
ment response and aid monitoring for disease progression and 
relapse (1,8‑14). A growing body of literature is additionally 
emerging on the role of specific placental‑derived miRNAs in 
pregnancy, particularly those complicated by processes such as 
gestational diabetes (15,16), gestational hypertension (17,18), 
pre‑eclampsia (19‑21) or congenital abnormalities (22,23).
miRNAs in biofluids, in particular serum and plasma 
derived from peripheral blood, are an attractive option for 
clinical biomarker development, as they are readily avail‑
able, relatively non‑invasive to obtain and widely processed 
in standard laboratory settings (24‑29). Compared with other 
potential biomarkers, miRNAs are excellent candidates, due 
to their stable expression both in vivo across a range of tissues 
and biofluids (26,30‑32), and ex vivo during differing storage 
conditions, being able to withstand ~48 h at room temperature 
or on ice (26,30), longer‑term storage at ‑80˚C (33,34) and 
their ability to undergo multiple (between 4‑8) freeze‑thaw 
cycles (26,30,31). Furthermore, due to the wide range of down‑
stream miRNA targets, with each mature miRNA being able 
to target ~200 mRNAs to exert their effects (9); their potential 
therapeutic capacity is simply vast (35).
In human pregnancy, there are three primary chromo‑
somal miRNA clusters located on chromosome 19 (C19MC, 
miR‑371‑3) and chromosome 14 (C14MC) which are highly 
and widely expressed in placental tissue and as circulating 
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markers, with the expression profile of these clusters varying 
during trimesters and gestational disease processes (21,36). 
MiRNAs are released from the trophoblastic layer into the 
maternal circulation in various forms, including microves‑
icle‑enveloped, in apoptotic bodies, exosomally or as protein 
bound miRNAs (37‑39), in order to avoid digestion by circu‑
lating RNAase enzymes (30,40‑42). Several commercially 
available miRNA isolation kits using serum and plasma 
capture the whole biofluid, including the exosomal component; 
the latter only representing a subset of the miRNAs found in 
this media (43‑45).
Although the discovery and validation of miRNA 
biomarkers remains at an experimental, pre‑clinical stage, there 
is a growing body of literature concerning the role of miRNAs 
in specific pregnancy‑associated conditions. However, there is 
little consensus regarding the optimal starting media or justifi‑
cation of the selection between serum or plasma (15,16,18,46). 
Most studies fail to acknowledge the potential differences in 
miRNA concentrations and profiles that may emerge when 
using serum vs. plasma as the starting biofluid (25‑27,33,47‑49), 
potentially inhibiting their successful applications in a clinical 
setting (26,27,47,48). Furthermore, several studies refer to 
serum or plasma interchangeably (25,41), whereas in fact they 
are quite different: Serum refers to the cell‑free blood compo‑
nent obtained following the activation of platelets and factors 
within the coagulation cascade, whereas plasma refers to the 
cell‑free blood component obtained prior to the coagulation 
process, hence collection tubes contain anticoagulants (EDTA 
or sodium citrate for downstream miRNA analysis) which 
inhibit the coagulation cascade (50). Heparinised tubes cannot 
be used for miRNA analysis as heparin inhibits downstream 
enzymatic reactions within the cDNA synthesis and reverse 
transcription (RT) steps of quantitative (q)PCR (33,45,49). The 
coagulation process itself can significantly alter a sample's 
miRNA profile and is a source of variability (for example, 
coagulation time and temperature) (27,33,47,49,50), which 
cannot be reliably controlled when using serum samples, 
leading several researchers to preferentially use plasma. 
Additionally, the coagulation process causes cell lysis and 
haemolysis, particularly from erythrocytes but also platelets, 
releasing RNA and miRNA into the serum, which affects the 
profile obtained (27,47,48). It is essential to acknowledge that 
haemolysis can also occur in both serum and plasma samples 
at the time of venepuncture, hence the need for standardised 
techniques to minimise this occurrence, including the use of 
larger gauge needles and well‑trained phlebotomists (51). For 
these reasons, haemolysis monitoring is a part of the standard 
quality control steps of sample preparation, either involving 
spectrophotometric or specific miRNA analysis (33,52‑54). 
Equally, the platelet content of plasma is an important 
consideration, given that their rich miRNA content may 
bias the determined outcome (24,27,47‑49), highlighting the 
importance of two centrifugation steps during sample prepa‑
ration to generate platelet‑poor as opposed to platelet‑rich 
plasma (7,49,55). One potential issue faced by miRNA 
researchers using pre‑collected samples is that the majority of 
archived blood samples have been collected as serum.
The optimum starting media is also crucially dependent 
upon the patient population under study, for example whether the 
individuals are healthy or diseased; pregnant or non‑pregnant. 
Different starting media may be more appropriate for specific 
patient types, which explains the contradiction between 
existing studies suggesting that either serum (studies involving 
healthy males, females and pregnant women) (25,27) or plasma 
(research involving patients with primary liver cancer or benign 
liver disease) (25,47) are superior.
To the best of our knowledge, there is only one comparable 
study examining the difference in miRNA concentrations and 
profiles between serum and plasma derived samples taken 
from pregnant women (25). However, this previous study 
analysed only three paired serum and plasma samples at one 
time point in pregnancy (second trimester) and generated 
conflicting outcomes dependent on whether the proportion or 
absolute number of detected miRNAs was measured. This is 
a key starting point which must be established before miRNA 
biomarkers can be reliably pinpointed as hallmarks of gesta‑
tional disease states. Therefore, the aim of the present study 
was to determine the optimum starting media at three key time 
points both intra and post‑partum, involving women with an 
uncomplicated, healthy pregnancy.
Patients and methods
Sample collection and RNA isolation. Blood samples were 
obtained from 10 pregnant women (median age 29.5 years, 
range 22‑34 years) with uncomplicated, low‑risk pregnancies 
at the following time points: i) during the second trimester of 
pregnancy (18‑24 weeks) n=2; ii) during weeks 36‑40 of the 
third trimester n=3; and iii) 6 weeks post‑partum, n=5. At each 
time point, blood was collected from each patient as follows: 
13.5 ml plasma in 3x4.5 ml sodium citrate vacutainer tubes 
(NHS Supply Chain) and 5 ml serum in a 5 ml SST vacutainer 
tube (NHS Supply Chain). Standard venepuncture procedures 
were followed, according to the National Cancer Institute 
Early Detection Research Network, which involved using a 
21‑gauge needle to minimise haemolysis (51,56). All low‑risk, 
healthy pregnant women referred to the antenatal clinic at the 
Jessop Wing, Sheffield Teaching Hospitals NHS Foundation 
Trust were eligible for inclusion in this study. Pregnant women 
were excluded from recruitment if: i) The pregnancy was dated 
>20 weeks gestation; ii) there was no foetal heartbeat detected 
on ultrasound imaging, or iii) there were known foetal anoma‑
lies. All samples were collected in the antenatal clinic of the 
Jessop Wing Hospital between January and September 2017. 
Following collection, samples were kept upright and stored 
on ice (maintained at ~4˚C) to inhibit miRNA degradation by 
circulating RNases within the whole blood, and were processed 
within 4‑6 h. Samples were centrifuged at 1,900 x g for 10 min 
at 4˚C and the recovered supernatant was aliquoted and imme‑
diately stored at ‑80˚C. Following gently thawing at room 
temperature, plasma samples underwent a second centrifuga‑
tion step (16,000 x g for 10 min at 4˚C) to generate platelet 
deficient plasma. Total RNA (including miRNA) was extracted 
from serum and plasma samples using a prototype version of the 
Maxwell® Rapid Sample Concentrator (RSC) miRNA Tissue or 
Plasma Serum kit (cat. no. AS1460; Promega Corporation) (57) 
with minor modifications to the standard protocol. Specifically, 
lyophilised DNase I was resuspended with 275 µl nuclease free 
water, mixing gently through inversion. A total of 5 µl Blue Dye 
was added to the reconstituted DNase I as a visual indicator, 
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swirling gently to mix. Aliquots were made and stored at 4˚C 
for a few weeks, or at ‑20˚C for longer storage. Subsequently, 
2.5 µl UniSp2, UniSp4 and UniSp6 (reconstituted according to 
manufacturer's instructions; Qiagen RNA spike in kit for RT; 
cat. no. 339390; Qiagen, Inc.) (58) was added to 200 µl binding 
buffer and mixed thoroughly. A total of 500 µl pre‑processed 
plasma was transferred to a 1.5 ml Eppendorf and 60 µl 
Proteinase K (Promega Corporation) was added. This was then 
combined with the binding buffer and spike‑in mix, vortexing 
for 10 sec. This sample lysate was then incubated at 37˚C for 
15 min. During this time, the Maxwell® RSC cartridges were 
prepared by removing their seals and loading them into the 
RSC deck tray. An RSC plunger was added to well 8 of each 
cartridge, 500 µl elution tubes were loaded into the deck and 
60 µl nuclease‑free water was added to each tube. A total of 
10 µl reconstituted DNAse I was added to well 4 (yellow) of the 
cartridges, before the total volume of incubated sample lysate 
was transferred into well 1 of the cartridges. The Maxwell® 
RSC Instrument (cat. no. AS4500: Promega Corporation) (59) 
instrument and the ‘RSC miRNA Tissue' method (60) was used 
to initiate the automated purification run. Following processing, 
the eluate was stored at ‑80˚C. Extracted RNA was assessed for 
quality and quantity using an Agilent Small RNA Chip and 
2100 Bioanalyzer (Agilent Technologies Deutschland GmbH), 
measuring miRNA percentage and concentration in pg/µl.
Ethics approval. Ethical approval for the present study 
(approval no. 16/NE/0292) was obtained from the United 
Kingdom North East Newcastle and North Tyneside 1 NHS 
Research Ethics Committee on 30/08/2016 and The Health 
Research Authority on 27/09/2016, with non‑substantial 
amendments approved on 18/10/2018 and 01/05/2019. Written 
informed consent was obtained from all patients.
miRNA quantification. cDNA synthesis was performed on the 
10 paired serum and plasma samples (2 replicates per sample; 
n=20 plasma cDNA, n=20 serum cDNA) using the qScript® 
microRNA cDNA Synthesis kit (Quantabio) according to the 
manufacturer's protocol, with one minor modification during 
the initial PolyA tailing reaction, specifically the addition of 
1 µl cel‑miR‑30‑3p and UniSp6 spike‑in mix (Qiagen, Inc.) 
reconstituted as per manufacturer's protocol. A total of 6 µl 
extracted RNA was used in each 10 µl PolyA tailing reac‑
tion. Reverse transcription‑quantitative (RT‑q)RT‑qPCR with 
a total reaction volume of 25 µl was performed as follows: 
0.5 µl PerfeCTa Universal Primer within the cDNA synthesis 
kit (Quantabio), 12.5 µl ExiLENT SYBR® Green MasterMix 
(Exiqon; Qiagen, Inc.), 2 µl cDNA, 9.5 µl nuclease‑free water 
and 0.5 µl of each of the 8 miRNA primers. Two quality control 
primers were used to assess the efficiency of RNA extraction 
(miRCURY LNA UniSp2 PCR assay) and cDNA synthesis 
(miRCURY LNA cel‑miR‑39‑3p) (Qiagen, Inc.), whereas 4 
miRNAs were chosen for the comparison between these starting 
media; hsa‑miR‑222‑3p, hsa‑miR‑23a, hsa‑miR‑30e‑5p and 
hsa‑miR‑451a (Integrated DNA Technologies, Inc.) (Table I). 
These four miRNAs were selected as they are known to be 
consistently and stably detected in biofluids such as serum 
and plasma (25,33,47); facilitating an assessment of their rela‑
tive quantity. hsa‑let‑7i‑3p and hsa‑miR‑148‑3p were chosen 
for normalisation. A 3‑step cycling qPCR protocol: 95˚C for 
2 min; followed by 40 cycles of 95˚C for 5 sec, 60˚C for 15 sec 
and 70˚C for 15 sec was used with a Bio‑Rad CFX96, Real 
time C1000 Touch Thermal Cycler (Bio‑Rad Laboratories, 
Inc.). RT‑qPCR involved no‑template (NTC) and no‑Reverse 
Transcriptase controls (NRTC).
Statistical analysis
Outliers. For each miRNA analysed, the mean Cq value and 
variance within each replicate was calculated. RT‑qPCR 
efficiency was calculated to be 2.0 and outliers (n=18) were 
removed accordingly (Table II).
Quality control. RNA extraction efficiency, monitored using 
UniSp2, was acceptable with Cq values showing consistent 
values (Δ<3 Cq) across the dataset (61). Haemolysis was 
monitored using ΔCq=mean Cqhsa‑miR‑23a‑mean Cqhsa‑miR‑451a, 
with a ΔCq >5 indicating possible haemolysis and a ΔCq >7 
conferring a high risk of haemolysis affecting the data 
obtained (26,33,61). Samples with a ΔCq >7 were excluded 
prior to further analysis. cDNA efficiency was acceptable 
with consistent values of cel‑miR‑39‑3p (Δ<2 Cq) across the 
dataset (61).
Relative expression. The relative expression (ΔCq) of each 
miRNA replicate was normalised against the geomean of 
two normalising miRNA (hsa‑let‑7i‑3p and hsa‑miR‑148‑3p), 
both of which are stably and consistently expressed in serum 
and plasma samples (33). Standard deviations and confidence 
intervals were calculated accordingly (62).
Analysis. Data were assessed for normality (Shapiro‑Wilk 
test) prior to statistical testing. If the Gaussian distribution was 
satisfied, a paired t‑test was performed, otherwise a Wilcoxon 
matched‑pairs signed rank test was used. Statistics were 
performed in GraphPad Prism version 8 (GraphPad Software, 
Inc.). P<0.05 was considered to indicate a statistically 
significant difference.
Results
Patient characteristics. Table III summarises the charac‑
teristics of the 10 patients (median age 29.5 years range 
22‑34 years) that provided paired serum and plasma samples 
taken at different time points during their uncomplicated 
low‑risk pregnancy.
Bioanalyzer miRNA content. Both the average concentration 
and percentage of miRNA was higher within serum compared 
to plasma samples (Fig. 1).
qPCR quality controls
Control samples. RNA extraction efficiency was deemed 
efficient with a ΔCq of UniSp2=2.88 across the dataset. As 
expected, a Cq result was not obtained for the NTC or NRTC 
samples, indicating that neither the starting serum or plasma 
samples, or the qPCR reagents were contaminated.
Haemolysis detection. None of the included samples displayed 
significant haemolysis (ΔCq=>7 Fig. 2) and were all retained 
for downstream analysis.
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Serum vs. plasma. Using ΔCq values and paired t‑tests, compari‑
sons were made between paired serum and plasma samples taken 
at each study time point to determine whether the miRNA profile 
differed between media. Only two comparisons were significant; 
specifically, the comparison between the paired serum and 
plasma samples at time point three, studying hsa‑miR‑30e‑5p 
(t=4.84, P=0.008) and hsa‑miR‑451a (t=3.27, P=0.03) (Fig. 3).
To determine whether serum or plasma samples yielded 
more consistent RT‑qPCR results, the standard deviations of the 
ΔCq values for paired serum and plasma samples taken at each 
study time point were compared, analyzing the four miRNAs 
of interest. Only one comparison was found to be significant, 
specifically the comparison between serum and plasma samples 
at time point two, using hsa‑miR‑30e‑5p. All other comparisons 
revealed no significant differences (P>0.05; Fig. 4).
Discussion
Selection of the most appropriate starting test sample for 
the identification of clinically relevant biomarkers is essen‑
tial, and is dependent upon first establishing the underlying 
performance of different starting substrates (26,45,47,48). In 
the present study. within a cohort of patients with uncompli‑
cated, low‑risk, healthy pregnancies, across the three study 
time points, the Bioanalyzer Small RNA chip data revealed 
the miRNA content of serum samples to be higher than that 
of plasma. Dissimilar to the Bioanalyzer findings, the majority 
of paired comparisons using RT‑qPCR showed no significant 
differences between the respective serum and plasma samples 
at any of the time points assessed. Only 2 comparisons out of 12 
were significant, specifically between paired serum and plasma 
samples taken at time point three, using hsa‑miR‑30e‑5p and 
hsa‑miR‑451a. Similarly, when comparing the consistency of 
serum vs. plasma samples, only 1 of the 12 comparisons was 
found to be statistically significant, involving time point two 
and hsa‑miR‑30e‑5p.
The only truly comparable previous manuscript involving 
a healthy pregnant population both agrees and disagrees with 
our findings. This previous study reported a higher proportion 
of miRNA in plasma compared to serum, although the abso‑
lute number of miRNAs detected and occurrence of abundant 
miRNA was higher in the serum (25) This previous study 
included 32 samples (20 serum, 12 plasma), yet only three 
paired serum and plasma samples from the same patient were 
obtained (25), reducing the generalisability and reliability of 
the results obtained, given the known intra and inter‑individual 
biological variability in the expression of certain miRNAs (63). 
Furthermore, the present study investigated three time points 
(and as such, determined whether the optimal starting media 
changed throughout pregnancy), as opposed to just one time 
point (second trimester) in the previous study (25).
Compared with the previous literature involving non‑preg‑
nant populations, the absence of a significant difference 
between serum and plasma samples using RT qPCR is in 
agreement with some studies (27,41,47,49,50), but in disagree‑
ment with others (7,25,33,48). However, direct comparisons 
cannot truly be made, given the known differences in miRNA 
expression profiles between different patient cohorts in terms 
of sex and disease states, with the above studies including 
lung, breast and colorectal cancer patients (7,41), healthy male 
or female subjects (7,27,41,48‑50). It is evident that when 
using only the existing literature, it is extremely challenging 
for researchers to deduce which starting media they should 
preferentially use to answer their research question.
Previous studies have suggested that serum samples 
collected and extracted in optimal conditions may display less 
Table I. Description of the 8 miRNA primers used for reverse transcription‑quantitative PCR.
miRNA primer Function Sequence
UniSp2 RNA extraction efficiency Unavailable
cel‑miR‑39‑3p cDNA synthesis efficiency 5'‑UCACCGGGUGUAAAUCAGCUUG‑3'
hsa‑miR‑451a Stably expressed miRNA of interest and detection of haemolysis 5'‑AAACCGUUACCAUUACUGAGUU‑3'
hsa‑miR‑23a Stably expressed miRNA of interest and detection of haemolysis 5'‑AUCACAUUGCCAGGGAUUUCC‑3'
hsa‑let‑7i‑3p Stably expressed miRNA used for normalisation 5'‑CUGCGCAAGCUACUGCCUUGCU‑3'
hsa‑miR‑148‑3p Stably expressed miRNA used for normalisation 5'‑UCAGUGCAUCACAGAACUUUGU‑3'
hsa‑miR‑222‑3p Stably expressed miRNA of interest 5'‑AGCUACAUCUGGCUACUGGGU‑3'
hsa‑miR‑30e‑5p Stably expressed miRNA of interest 5'‑UGUAAACAUCCUUGACUGGAAG‑3'
Table II. Method of identifying RT‑qPCR data outliersa.
 Maximal acceptable












aFor each miRNA replicate, the mean Cq value and variance was 
calculated and outliers removed accordingly. RT‑qPCR efficiency 
was calculated to be 2.0. RT‑qPCR, reverse transcription‑quantitative 
PCR.
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variation in the miRNA data than plasma samples (33); however 
the results of the present study did not replicate this, showing 
no significant differences between the standard deviations of 
normalised serum and plasma data based on RT‑qPCR.
Regarding the results of the present study, the discrepancy 
between quantification techniques is potentially explained 
by the uncontrolled and variable release of miRNAs from 
erythrocytes and platelets during the coagulation process 
within serum samples, which may have contributed to the 
higher miRNA levels observed with the Small RNA chip 
data (27,33,45,47,48,50). This is corroborated by the higher 
mean haemolysis levels for serum samples compared with 
plasma, with the ΔCq (hsa‑miR‑23a and hsa‑miR‑451a) being 
5.78 and 4.76, respectively. The chips used within the Agilent 
Bioanalyzer each comprise a network of capillary channels 
that separate the sample by means of gel electrophoresis. The 
principle is based upon the fact that small fragments migrate 
faster than larger ones, using fluorescent dye molecules that 
intercalate with the RNA strands. These hybrid molecules 
are detected by their fluorescence and translated into gel‑like 
images (bands) and electropherograms (peaks). Small RNA 
chips measure RNA of 6‑150 nucleotides in size, and quan‑
tify the concentration and percentage of miRNA within a 
sample based on the number of molecules falling within the 
4‑39 nucleotide region (64); however this pre‑defined region 
for detection may additionally contain small interfering 
RNA (20‑25 nucleotides in length) or degraded longer RNA 
molecules including small nuclear RNA (~100 nucleotides), 
primitive (pri‑miRNA, several hundred nucleotides) or 
precursor miRNA (~70 nucleotides) (65), which could falsely 
elevate the quantification of miRNA. Dissimilarly, RT‑qPCR 
using specific primers would only bind and amplify mature 
miRNA molecules with a sequence that precisely matches the 
primer assay, meaning that even isomers of the miRNA may 
not be detected (66). This is particularly problematic when 
profiling miRNAs, given there are >3,000 known miRNA vari‑
ants, most of which differ from the official sequence as denoted 
on miRBASE, from which the majority of RT‑qPCR primer 
assays are designed (67,68). Furthermore, existing studies have 
shown key differences between the varying methods of quan‑
tifying RNA and DNA libraries, with electrophoresis‑based 
quantification techniques (including the Agilent Bioanalyzer) 
producing higher concentration estimates (69) or highly vari‑
able quantification results (70) compared with RT‑qPCR or the 
Qubit fluorometer. Overall, RT‑qPCR is suggested to generate 
more reliable results, notwithstanding the increased number 
Figure 2. Haemolysis analysis for the included samples, where ΔCq=mean 
Cqhsa‑miR‑23a‑mean Cqhsa‑miR‑451a. ΔCq >5 indicates possible haemolysis and 
ΔCq >7‑8 confers a high risk of haemolysis.
Figure 1. Bioanalyzer data. (A) miRNA concentration as the median + 
95% confidence interval of the serum vs. plasma samples measured using the 
Agilent Bioanalyzer Small RNA chip. n=20. Wilcoxon matched pairs signed 
rank test, P=0.0039. A Shapiro‑Wilk test of normality was passed for plasma 
(W=0.95, P=0.65) but not for serum (W=0.65, P=0.0002). (B) MiRNA 
percentage as the mean + standard deviation of serum vs. plasma samples 
measured using the Agilent Bioanalyzer Small RNA chip. n=20. A two‑tailed 
paired t‑test was used to compare data (t=4.97, P=0.0008, df=9). Shapiro‑Wilk 
test of normality was passed for both plasma and serum (plasma W=0.97, 
P=0.84; serum W=0.95, P=0.67). *P<0.05. miRNA, microRNA.
Table III. Summary characteristics of recruited patientsa.
Study time point n Average gestational age, weeks + days Range, weeks + days
Second trimester 2 18+4 17+5‑19+1
Third trimester 3 38+1 37+5‑39+2
6 weeks post‑partum 5 6.3 weeks post delivery 5‑7 weeks
an=10.
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Figure 4. Consistency comparison: Comparing the ΔCq standard deviations of paired serum and plasma samples across the three study time points, analysing 
four stably expressed miRNAs; hsa‑miR‑222‑3p, hsa‑miR‑23a, hsa‑miR‑30e‑5p and hsa‑miR‑451a. *P<0.05. miRNA/miR, microRNA; 1, second trimester of 
pregnancy (18‑24 weeks); 2, weeks 36‑40 of the third trimester; 3, 6 weeks post‑partum.
Figure 3. Comparison between the ΔCq of paired serum and plasma samples, as the mean + standard deviation, across the three study time points, analysing 
four stably expressed miRNAs; hsa‑miR‑222‑3p, hsa‑miR‑23a, hsa‑miR‑30e‑5p and hsa‑miR‑451a. *P<0.05. miRNA/miR, microRNA; 1, second trimester of 
pregnancy (18‑24 weeks); 2, weeks 36‑40 of the third trimester; 3, 6 weeks post‑partum.
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of replicates performed using this technique and the high 
between‑run variability that was noted with the Bioanalyzer 
in the present study.
Limitations of the present study include the relatively 
small sample size of 10 pregnant patients; however this is in 
keeping with the sample sizes of existing literature (27,48‑50) 
and is strengthened by the presence of paired samples taken at 
exactly the same time points, and being stored and processed 
using the same conditions. Despite this, a larger patient cohort 
would have been preferable, particularly considering time 
point i), which involved only two patients, potentially limiting 
the generalisability of the data obtained and capacity to detect 
a true difference. Although a significant difference was not 
observed between the paired serum and plasma samples, it 
would have been preferable to match the baseline character‑
istics of the patients more closely, in terms of age, body mass 
index and the exact gestation at which the samples were taken, 
yet previously published literature have similarly not corrected 
for these factors (25,27,47). There is also no consensus on the 
optimal normalisation strategy when working with miRNA 
RT‑qPCR data, leading to further variability and difficulty 
when comparing with existing studies (24,71,72). The 
approach taken here, to normalise to two stably expressed 
miRNAs (hsa‑let‑7i‑3p and hsa‑miR‑148‑3p) across the serum 
and plasma samples, is a recognised approach that is prefer‑
able to the use of synthetic spike‑ins, such as cel‑miR‑39‑3p. 
Such synthetic spike‑ins are useful to identify differences in 
RNA extraction efficiency, but not to normalise the endog‑
enous miRNA content of the sample (24,58,73). The use of two 
normalising miRNAs was further acceptable for the present 
study given that all RNA extractions were performed within 
the same batch. However, when this is not the case, and with 
greater resources, normalising to 3‑5 miRNAs that are stably 
expressed within the starting media, or better still, normalising 
to the global mean of >90 miRNAs is preferred (33,45,71).
Future work should involve replicating the experiments 
using a larger patient population, and using a more stringent 
cut‑off of ≤5 for the ΔCq for the haemolysis markers on 
RT‑qPCR, which may reduce the potential to falsely elevate 
the miRNA content of serum samples, yet most clinical studies 
would accept ΔCq <7 (26,33).
It is clear that the choice of starting media for ongoing 
experiments is crucially dependent on three main factors: 
i) sample type; ii) the patient cohort under investigation 
(healthy vs. disease; pregnant vs. non‑pregnant); and iii) the 
miRNA quantification technique. As seen in the present 
study, different miRNA quantification techniques can produce 
conflicting information concerning the optimal starting 
media, and scientists should be astutely aware of this when 
designing studies, particularly those with a clinical end 
point. In the healthy pregnant population using the Agilent 
Bioanalyzer, the present study showed there to be a higher 
miRNA concentration and percentage in serum samples. 
However, this was not replicated in the RT‑qPCR results, 
which, due to the detection of specific miRNAs, is suggested 
to be more reliable and less liable to the incorrect inclusion of 
fragmented long RNA molecules or miRNAs released during 
the coagulation process. Furthermore, RT‑qPCR involves a 
higher number of replicates, and this increases the reliability of 
the results, producing consistent data unlike the high between 
run variability that was observed in the present study using 
the Bioanalyzer. In view of this, it is concluded that neither 
serum nor plasma are superior starting media during the intra 
or post‑partum period in the healthy pregnant population, and 
as such, either would be suitable for studies and downstream 
analyses investigating the miRNA profiles or use of clinical 
biomarkers in this population.
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